Michael J. Thomas

Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)

Ajay K. Kakkar, Mark N. Levine, Zbigniew Kadziola et al. · Journal of Clinical Oncology · 2004 · 654 citations · Full text

Medicine, Oncology, Pharmacology +13

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Martin Reck, Alexander Luft, Aleksandra Szczęsna et al. · Journal of Clinical Oncology · 2016 · 537 citations

Medicine, Oncology, Pharmacotherapy +8

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 375 citations · Full text

Medicine, Oncology, Pharmacology +14

Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe–/– mice during disease regression

Stéphane Potteaux, Emmanuel L. Gautier, Susan Hutchison et al. · Journal of Clinical Investigation · 2011 · 333 citations · Full text

Life Sciences, Cell Biology, Immunology +17